NEW YORK – CLX Health and Quest Diagnostics said Tuesday that they are collaborating to provide COVID-19 molecular testing for international travelers and attendees of live events.
Under the collaboration, individuals will be able to schedule testing appointments at Quest patient centers and retail partner locations using CLX's TrustAssure Global Testing Platform. Results will be provided within 48 hours in advance of an event or travel date.
Quest is the first national COVID-19 molecular testing provider to participate in the TrustAssure platform.
"We're excited to continue to build our global testing platform with Quest Diagnostics as a collaborator in the United States. Their national capabilities will provide American consumers access to testing in key markets across the country," Joseph Gonzalez, chief strategy officer for CLX Health, said in a statement. "We are committed to developing solutions to meet testing requirements and ensure a safe travel experience for our clients and their customers around the world."
"COVID-19 testing is a powerful tool for providing insights that can foster safer environments," said Cathy Doherty, senior VP and group executive, clinical franchise solutions and marketing, at Quest. "As COVID-19 restrictions are lifted around the country and world, our collaboration with TrustAssure will allow us to facilitate high-quality testing for individuals looking to get back to recreation and travel."
Financial and other terms of the agreement were not disclosed.